HS Pipeline Watch: Izokibep Meets Primary Endpoint in Global Phase 3 Trial

Izokibep, Affibody’s next-generation interleukin (IL)-17A inhibitor, performed well in hidradenitis suppurativa (HS), according to 32-week data from a global Phase 3 study presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO.